Vitamin E is required by very low birth weight (VLBW) infants to prevent vitamin E deficiency. However, prolonged intravenous intakes of vitamin E >4 international units (IU)/kg/day often yield potentially toxic serum tocopherol levels. This study was designed to assess the frequency of potentially inadequate or excessive doses of intravenous vitamin E in parenteral nutrition for VLBW infants in the US.
INTRODUCTION
An adequate intake of vitamin E is required by very low birth weight (VLBW) infants to prevent vitamin E deficiency, which is characterized by hemolytic anemia, edema, thrombocytosis and rarely spinocerebellar degeneration. When enteral vitamin E supplementation is not possible, infants require intravenous multivitamins containing vitamin E.
Recommended doses of intravenous multivitamins in VLBW infants vary considerably [1] [2] [3] [4] [5] and may provide vitamin E intakes known to be associated with toxicity. 6 The American Academy of Pediatrics (AAP) until recently recommended 2.8 international units (IU)/day vitamin E for all infants <2.5 kg. 1 This intake would provide 7 IU/kg/day for a 0.4-kg infant.
Intakes of intravenous vitamin E >4 IU/kg/day often yield potentially toxic serum tocopherol levels (>81 mmol/l or 3.5 mg/dl) after 2 to 3 weeks of administration. 6 Two recent systematic reviews have shown that vitamin E supplementation significantly reduces the risk of severe retinopathy of prematurity among VLBW infants who were examined for retinopathy. 7, 8 One of these reviews 8 reported significantly (50%) increased risk of culture-proven sepsis with vitamin E supplementation. Subgroup analysis 8 showed that vitamin E supplementation in VLBW infants resulting in levels >81 mmol/l (3.5 mg/100 ml) significantly reduces the risk for severe retinopathy among infants who were examined for retinopathy, but increases the risk of sepsis in all infants and the risk of necrotizing enterocolitis among infants treated for >1 week. In contrast, vitamin E supplementation resulting in levels <81 mmol/l does not significantly affect any of these outcomes. These data suggest that vitamin E supplementation may reduce the risk of severe retinopathy of prematurity but only at high, toxic serum levels. In 2003, dose recommendations for intravenous multivitamin in VLBW infants varied considerably, and no data were available regarding compliance with any of these recommendations. This survey was designed to assess the frequency with which potentially inadequate or potentially toxic doses of intravenous vitamin E were routinely used in parenterally fed VLBW infants in neonatal-perinatal training program centers in the US in 2003.
METHODS
In 2003, a questionnaire was sent twice by fax to 100 neonatalperinatal training program centers listed in the 2003 directory (AAP, Section on Perinatal Pediatrics), and up to three times by e-mail to the 92 division directors of the same centers for whom an e-mail address was available. We used these two routes for each center with the hope of increasing the percentage of responses and of obtaining information from different sources in the same center, thereby checking the consistency of the response. In addition, the centers that did not respond to e-mail or fax request were contacted by telephone. Altogether, 100 centers were entered into the database. We compare neonatal intensive care unit (NICU) level and availability of obstetrical service between responding and nonresponding centers. For this purpose, we used the following database: http://www.neonatology.org/pdf/NeonatalFellowships.pdf.
We compared the responses with the doses recommended by: 2. The AAP recommendation published in 1998 1 (AAP 1988): For infants with body weight <2.5 kg, 2 ml of M.V.I.
s Pediatrict solution, which yields 2.8 IU/day of vitamin E. For infants >2.5 kg, 5 ml/day of M.V.I.
s Pediatrict or 7 IU/day of vitamin E. 3. The recommendation from Astra Pharmaceuticals: 4 For infants weighing <1 kg, 1.5 ml/day (30% of a vial) of M.V.I. s Pediatric,t which yields 2.1 IU/day of vitamin E. For infants weighing Z1 kg and <3 kg, 3.25 ml/day (65% of a vial) of M.V.I.
s Pediatrict solution, which yields 4.55 IU/day of vitamin E. For infants Z3 kg, 5 ml/day (a whole vial) of M.V.I. s Pediatrict solution, which yields 7 IU/day of vitamin E.
4. The recommendations from Sabec Inc: 5 For infants <1 kg, 1.2 ml (30% of a vial 1) of Infuvite Pediatric,t which yields 2.1 U/day of vitamin E. For infants Z1 and <3 kg, 2.6 ml (65% of a vial 1) of Infuvite Pediatric,t which yields 4.55 IU/day of vitamin E. For infants Z3 kg, 4 ml/day (a whole vial) of Infuvite Pediatric,t which yields 7 IU/day of vitamin E.
The schedule used in each NICU was entered onto a spreadsheet to calculate the doses per kg of vitamin E that VLBW infants of three body weights (i.e., 0.5, 1.0 and 1.5 kg) would be predicted to receive while being given intravenous nutrition with M.V.I. rate-dependent dose, we assumed a total daily intravenous fluid intake of 150 ml/kg/day. Statistical analysis was performed using two-tailed tests and considering a p-value less than 0.05 as significant. Comparison of the vitamin E doses by weight was first performed by analysis of variance (ANOVA or Kruskal-Wallis ANOVA depending on data distribution, i.e., normal or not) using SPSS for Windows version 12 (SPSS, Inc., Chicago, IL). Doses of vitamin E administration were then recoded as a categorical variable on the basis of the ASCN 1988/AAP 2004 recommendation (2.8 IU/kg/day) and on the dose (>4 IU/kg/day) often associated with potentially toxic serum tocopherol levels, 6 that is, below 2.8 IU/kg/day, between 2.8 and 4.0 IU/kg/day, and above 4.0 IU/kg/day. We tested the null hypothesis of equality of distribution of the dose of vitamin E against ordered body weight, by using the linear-by-linear association test, and calculated the exact value of probability. w 2 analysis was performed by exact test using StatXact 6 (Cytel Statistical Software, Cambridge, MA, USA).
RESULTS
Respondents were identified as 48 program directors or division directors, four other neonatologists, four pharmacists and one dietitian; 16 could not be identified. After correcting for five overlapping responses (either two faxes or one e-mail and one fax), we counted 67 responses, including two different responses (one per NICU) for NICUs within the same training program and five that could not be identified because an anonymous response had been obtained. Within the available database, centers identified as having responded were, in comparison with centers that either did not respond or could not be identified, more likely to be of level IIID (hospitals offering cardiac surgery and ECMO) (51/60 vs 27/40, p ¼ 0.0498), but equally likely to be a free standing children's hospital without obstetrical service (12/60 vs 10/40, NS).
Multivitamin administration was started on the first or second day of life in all NICUs (n ¼ 67). M.V.I.
s Pediatrict was used by 64 NICUs and Infuvite Pediatrict by three NICUs. Consistency in responses when more than one response to the survey was obtained from the same center could be checked in four NICUs and was confirmed in each case. Specifically, in two cases we compared the information provided by the program director and by the pharmacist, and in two cases the information provided by the same individual on two different occasions (same handwriting but different text). In addition, in four NICUs, information by the program director or a neonatologist was directly confirmed by the policy or by the order sheet used in the unit.
Among these 67 NICUs, 30 (45%) followed the ASCN 1988 recommendation, three (4%) followed the AAP 1998 recommendation, 11 (16%) used the recommendations from Astra Phamaceuticals and Sabec Inc., and 23 (34%) followed one of 21 different protocols, which were similar to one of the above recommendations or to one of the previously published protocols. 6 The basis of the schedule was a fixed dose per kg in 37 NICUs (55%), stepped weight-based dosing in 22 NICUs (33%), a fixed dose regardless of weight in six NICUs (9%) and a total parenteral nutrition (TPN)-rate-dependent dose in two units (3%).
The predicted dose of vitamin E per kg of body weight did not have a normal distribution and was not significantly different among the three body weights ( p ¼ 0.12, Kruskal-Wallis ANOVA).
The median values were all 2.8 IU/kg/day regardless of body weight, and minimum values were all 0.7 IU/kg/day. Maximum values were 9.2 IU/kg/day for a 0.5-kg infant, 4.9 IU/kg/day for a 1.0-kg infant and 5.3 IU/kg/day for a 1.5-kg infant.
In contrast, the distribution of vitamin E dose recoded as a categorical variable was significantly associated with body weight (Table 1) , with more frequent excessive doses at lower weight ( p ¼ 0.0008).
DISCUSSION
This survey of neonatal-perinatal training programs in the US, especially those with level IIID NICUs, showed that in 2003 the median vitamin E intake provided to VLBW infants by routine i.v. multivitamins in TPN was the same as the dose recommended by the ASCN in 1988, 2 that is, 2.8 IU/kg/day. Among six NICUs (9%) providing a fixed daily intravenous dose of vitamin E, that is, a dose not based on weight, three followed the AAP 1998 recommendation. 1 The administration of a fixed daily dose of vitamin E has been shown to result in an inverse relationship between serum tocopherol level and birth weight 9,10 and after sufficient duration presents risks for both low and high serum tocopherol levels. Intravenous doses of vitamin E >4 IU/kg/day were provided to 500-, 1000-and 1500-g infants, respectively, in 40, 31 and 10% of the NICUs. Previous data have shown that doses of vitamin E >4 IU/kg/day often yield high serum tocopherol levels, 6 which in turn significantly increase the risk for sepsis and necrotizing enterocolitis in infants receiving vitamin E for more than 1 week. 7 Fewer than 20% of the NICUs used doses that are too low and might lead to manifestations of vitamin E deficiency. 6 Toxic doses of vitamin E increase the risk of infection and hemorrhage by at least three mechanisms: (1) decreased leukocyte function, including decreased generation of superoxide anion, (2) a decrease in vitamin K-dependent factors in vitamin K-deficient individuals and (3) inhibition of platelet prostaglandin synthesis and of platelet aggregation. 6 In addition, toxic doses of polysorbate 80 reduce in vitro responses of human lymphocytes to phytohemagglutinin. 11 Since current intravenous multivitamin solutions contain 50 mg polysorbate 80 per 7 IU tocopherol, the maximum dose of vitamin E (9.2 IU/kg/day) reported in this survey would provide 66 mg/kg/day of polysorbate 80, a dose that approaches doses given to patients symptomatic from E-Ferol (minimum reported dose 76 mg/kg/day of polysorbate 80 with 21 IU/kg/day of vitamin E). 12 Prolonged excessive dosage of parenteral vitamin E or multivitamin solution might be especially concerning, potentially increasing the risk of necrotizing enterocolitis. 8 In 2004, that is, after this survey was conducted, the AAP endorsed the ASCN 1988 recommendation, that is, a dose of 2.8 IU/ kg/day, 3 which can be provided either by 2 ml/kg/day of M.V.I. 2,3 Consideration should be given to provide pharmacologic doses of vitamin A (without additional vitamin E) to VLBW infants during the first weeks of life to reduce the risk for bronchopulmonary dysplasia. 6, 13 In summary, this survey showed a lack of uniformity of dosing of intravenous vitamin E in VLBW infants. The smallest infants (<1.0 kg) were receiving excessive, potentially toxic doses of vitamin E in a significant number of NICUs in the US in 2003. 
